GLABF (Gemina Laboratories) Debt-to-Equity: -0.05 (As of Oct. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Gemina Laboratories Debt-to-Equity?

Gemina Laboratories GLABF -27.59% Debt-to-Equity is -0.05 as of Oct. 2025. The stock has 2 warning signs investors should review.

Gemina Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2025 was $0.17 Mil. Gemina Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2025 was $0.00 Mil. Gemina Laboratories's Total Stockholders Equity for the quarter that ended in Oct. 2025 was $-3.68 Mil. Gemina Laboratories's debt to equity for the quarter that ended in Oct. 2025 was -0.05.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Gemina Laboratories's Debt-to-Equity or its related term are showing as below:

GLABF' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.35   Med: -0.05   Max: 3.31
Current: -0.05

During the past 5 years, the highest Debt-to-Equity Ratio of Gemina Laboratories was 3.31. The lowest was -3.35. And the median was -0.05.

GLABF's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.16 vs GLABF: -0.05

Gemina Laboratories  (OTCPK:GLABF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Gemina Laboratories Debt-to-Equity Related Terms

Gemina Laboratories Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Gemina Laboratories's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gemina Laboratories Debt-to-Equity Chart

Gemina Laboratories Annual Data
Trend Jan21 Jan22 Jan23 Jan24 Jan25
Debt-to-Equity
0.62 0.05 -3.33 -0.31 -0.29

Gemina Laboratories Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.42 -0.29 -0.06 -0.05 -0.05

GLABF vs VRTX, REGN, ALNY: Debt-to-Equity Comparison

For the Biotechnology subindustry, Gemina Laboratories's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gemina Laboratories Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gemina Laboratories's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Gemina Laboratories's Debt-to-Equity falls into.


Gemina Laboratories Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Gemina Laboratories's Debt to Equity Ratio for the fiscal year that ended in Jan. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.763 + 0.122) / -3.082
=-0.29

Gemina Laboratories's Debt to Equity Ratio for the quarter that ended in Oct. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.172 + 0) / -3.676
=-0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -0.05 mean?
Gemina Laboratories (GLABF) has a Debt-to-Equity of -0.05 as of Oct. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Gemina Laboratories and its competitors.
Is Gemina Laboratories' Debt-to-Equity too high?
Gemina Laboratories' current Debt-to-Equity is -0.05.
How does Gemina Laboratories' Debt-to-Equity compare to VRTX and REGN?
Gemina Laboratories' Debt-to-Equity of -0.05 can be compared against companies in the Biotechnology industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Gemina Laboratories and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gemina Laboratories's current Debt-to-Equity is -0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gemina Laboratories stock overvalued right now?
Gemina Laboratories (GLABF) has a current Debt-to-Equity of -0.05. The current Debt-to-Equity is -0.05. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Gemina Laboratories (GLABF), the current Debt-to-Equity is -0.05 as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gemina Laboratories Business Description

Address 3600 Gilmore Mall, Suite 302, Burnaby, BC, CAN, V5G 4R8
Gemina Laboratories Ltd is a biotechnology company that operates in the In Vitro Diagnostics (IVD) and human wellness monitoring market under the name Gemina Labs. The company endeavors to develop novel surface functionalization chemistries for the detection of pathogens and biomarkers.